Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome

Main Article Content

Philip J. Mease
Gülen Hatemi
Maria Paris
Sue Cheng
Peter Maes
Wendy Zhang
Rebecca Shi
Andrea Flower
Linda Stein Gold
Dawn Nicewarner
a:1:{s:5:"en_US";s:10:"Amgen Inc.";}

Keywords

Psoriasis, Psoriatic Arthritis, Behçet’s Syndrome, Oral Ulcers, Apremilast, safety

References

1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.; 2021.

2. European Medicines Agency. Otezla Summary of Opinion (post authorisation) Amsterdam, The Netherlands: European Medicines Agency; 2020.

3. Otezla EPAR summary for the public: European Medicines Agency; 2015.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.250

Article Details

How to Cite
[1]
Mease, P.J. , Hatemi, G. , Paris, M. , Cheng, S. , Maes, P. , Zhang, W., Shi, R. , Flower, A. , Gold, L.S. and Nicewarner, D. 2023. Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behçet’s Syndrome. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s250. DOI:https://doi.org/10.25251/skin.7.supp.250.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Poster Presentations from FC23 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>